In the context of pharmaceutical companies, Steve Woodruff discusses the tradeoffs of a personalized Twitter feed versus a homogenized feed on KevinMD:
As more and more pharmaceutical companies dip their toes into social media, one of the issues that surfaces regularly is this: do you put someONE in charge of a blog and/or Twitter account, or do you make it more anonymous? Or something else?
